Watson seeks to market generic Avodart

Watson Pharmaceuticals has confirmed that one of its units has filed an ANDA with the FDA seeking approval to market dutasteride capsules, 0.5 mg. The capsules are a generic version of GlaxoSmithKline's Avodart, which is indicated for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate. GSK has filed suit to block the generic challenge. Watson release